A large number of studies have demonstrated that the T cell checkpoint protein PD-L1 is degraded through either proteasome- or lysosome- pathways and cancer cell inhibits PD-L1 degradation via PD-L1 glycosylation, palmitoylation, or many other mechanisms45–48. Here, CD274 is linked to cancer.